MFJ Stock Overview
Designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
MFJ passed our risk checks.
My Notes
Capture your thoughts, links and company narrative
PolyNovo Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$1.24 |
| 52 Week High | AU$1.61 |
| 52 Week Low | AU$0.90 |
| Beta | 1.72 |
| 1 Month Change | -3.88% |
| 3 Month Change | -22.01% |
| 1 Year Change | 24.62% |
| 3 Year Change | 30.53% |
| 5 Year Change | 6.90% |
| Change since IPO | 122.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| MFJ | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 9.7% | 0.1% | 0.5% |
| 1Y | 24.6% | -7.5% | 7.2% |
Return vs Industry: MFJ exceeded the German Medical Equipment industry which returned -8.4% over the past year.
Return vs Market: MFJ exceeded the German Market which returned 7% over the past year.
Price Volatility
| MFJ volatility | |
|---|---|
| MFJ Average Weekly Movement | 5.6% |
| Medical Equipment Industry Average Movement | 6.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MFJ has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: MFJ's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 254 | Swami Raote | polynovo.com |
PolyNovo Limited designs, manufactures, and sells biodegradable medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, a dermal scaffold for the regeneration of the dermis when lost through extensive surgery, trauma, or burn. It is also developing hernia devices for hernia repair and solution for ventral hernia and complex abdominal wall reconstruction; NovoSorb Dermal Beta Cell, a novel intracutaneous ectopic pancreas to treat type 1 diabetes; NovoSorb MTX for single stage grafting in burns, chronic, and surgical wounds; and plastics and reconstructive device products.
PolyNovo Limited Fundamentals Summary
| MFJ fundamental statistics | |
|---|---|
| Market cap | €885.32m |
| Earnings (TTM) | €3.14m |
| Revenue (TTM) | €61.54m |
282.3x
P/E Ratio14.4x
P/S RatioIs MFJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MFJ income statement (TTM) | |
|---|---|
| Revenue | AU$103.23m |
| Cost of Revenue | AU$16.41m |
| Gross Profit | AU$86.82m |
| Other Expenses | AU$81.56m |
| Earnings | AU$5.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0076 |
| Gross Margin | 84.11% |
| Net Profit Margin | 5.10% |
| Debt/Equity Ratio | 3.6% |
How did MFJ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 05:19 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PolyNovo Limited is covered by 10 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | Bell Potter |
| Lyanne Harrison | BofA Global Research |
| Andrew Paine | CLSA |